We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 108.00 | 0.90% | 12,170.00 | 12,172.00 | 12,174.00 | 12,266.00 | 12,054.00 | 12,194.00 | 870,971 | 16:35:22 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.69 | 188.69B |
From May 2019 to May 2024
By Ian Walker
AstraZeneca PLC (AZN.LN) said Tuesday that it is selling the rights to acid-reduction drug Losec to Cheplapharm Arzneimittel GmbH for an initial $243 million.
The pharmaceutical giant is selling the global commercial rights to Losec, excluding China, Japan, the U.S. and Mexico.
Under the deal Astra will receive milestone payments of up to $33 million in 2021 and 2022, subject to certain sales targets being met.
Astra said the sale, which is part of the board's strategy to reduce the portfolio of mature medicines, doesn't change its financial guidance for 2019.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
October 01, 2019 02:41 ET (06:41 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
